AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s stock had its “outperform” rating reaffirmed by equities researchers at FBR & Co in a report issued on Saturday. They currently have a $3.00 price target on the biopharmaceutical company’s stock. FBR & Co’s price target suggests a potential upside of 417.15% from the stock’s previous close.
AVEO Pharmaceuticals (NASDAQ:AVEO) traded down 1.6780% during trading on Friday, reaching $0.5801. 469,257 shares of the company traded hands. The firm has a 50-day moving average price of $0.72 and a 200-day moving average price of $0.68. AVEO Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $1.15. The company’s market capitalization is $44.01 million.
In other news, major shareholder Equity Opportunities Iv Growth bought 6,000,000 shares of the firm’s stock in a transaction dated Tuesday, March 28th. The stock was acquired at an average price of $0.50 per share, for a total transaction of $3,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 5.10% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in shares of AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock worth $1,482,000 after buying an additional 148,500 shares during the last quarter. Sarissa Capital Management LP acquired a new position in shares of AVEO Pharmaceuticals during the fourth quarter worth about $917,000. New Leaf Venture Partners L.L.C. acquired a new position in shares of AVEO Pharmaceuticals during the fourth quarter worth about $1,399,000. Finally, Perceptive Advisors LLC acquired a new position in shares of AVEO Pharmaceuticals during the fourth quarter worth about $1,678,000. Hedge funds and other institutional investors own 37.94% of the company’s stock.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.